Public Health Research Institute Center
Associate Professor & Director of Antimicrobial Drug Discovery
New Jersey Medical School - Rutgers, The State University of New Jersey
225 Warren Street
Newark, New Jersey 07103
Phone: (973) 854-3220
We are living in the perfect storm: Resistance of bacteria against antibiotics is increasing and the drug discovery pipelines in industry are empty. There is an urgent medical need for the discovery and development of new antibacterials. This lab is interested in understanding the molecular mechanisms of antibiotic resistance and in exploiting this knowledge for the discovery of new antibacterials. A major focus is the identification of novel lead – target couples for lead optimization campaigns with the objective of delivering preclinical development compounds. The disease area of interest are mycobacterial infections: Tuberculosis (TB) and lung disease caused by Non-Tuberculous Mycobacteria (NTM).
Yee M, Gopal P, Dick T (2017) Missense Mutations in the Unfoldase ClpC1 of the Caseinolytic Protease Complex Are Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 61. PMI: 27872068
Yang T, Moreira W, Nyantakyi SA, Chen H, Aziz DB, Go ML, Dick T (2017) Amphiphilic Indole Derivatives as Antimycobacterial Agents: Structure-Activity Relationships and Membrane Targeting Properties. J Med Chem. PMI: 28290692
Yamada Y, Dick T (2017) Mycobacterial Caseinolytic Protease Gene Regulator ClgR Is a Substrate of Caseinolytic Protease. mSphere 2. PMI: 28317028
Moreira W, Santhanakrishnan S, Ngan GJ, Low CB, Sangthongpitag K, Poulsen A, Dymock BW, Dick T (2017) Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity Against the Human Proteasome. Antimicrob Agents Chemother. PMI: 28193668
Gopal P, Tasneen R, Yee M, Lanoix JP, Sarathy J, Rasic G, Li L, Dartois V, Nuermberger E, Dick T (2017) In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1. ACS Infect Dis. PMI: 28271875
Wu ML, Gengenbacher M, Dick T (2016) Mild Nutrient Starvation Triggers the Development of a Small-Cell Survival Morphotype in Mycobacteria. Front Microbiol 7: 947. PMI: 27379076
Wu ML, Gengenbacher M, Chung JC, Chen SL, Mollenkopf HJ, Kaufmann SH, Dick T (2016) Developmental transcriptome of resting cell formation in Mycobacterium smegmatis. BMC Genomics 17: 837. PMI: 27784279
Wu ML, Chan CL, Dick T (2016) Rel Is Required for Morphogenesis of Resting Cells in Mycobacterium smegmatis. Front Microbiol 7: 1390. PMI: 27630635
Mukherjee D, Zou H, Liu S, Beuerman R, Dick T (2016) Membrane-targeting AM-0016 kills mycobacterial persisters and shows low propensity for resistance development. Future Microbiol 11: 643-650. PMI: 27158932
Moreira W, Lim JJ, Yeo SY, Ramanujulu PM, Dymock BW, Dick T (2016) Fragment-Based Whole Cell Screen Delivers Hits against M. tuberculosis and Non-tuberculous Mycobacteria. Front Microbiol 7: 1392. PMI: 27656168
Moreira W, Aziz DB, Dick T (2016) Boromycin Kills Mycobacterial Persisters without Detectable Resistance. Front Microbiol 7: 199. PMI: 26941723
Kundu S, Biukovic G, Gruber G, Dick T (2016) Bedaquiline Targets the epsilon Subunit of Mycobacterial F-ATP Synthase. Antimicrob Agents Chemother 60: 6977-6979. PMI: 27620476
Koh JJ, Zou H, Mukherjee D, Lin S, Lim F, Tan JK, Tan DZ, Stocker BL, Timmer MS, Corkran HM, Lakshminarayanan R, Tan DT, Cao D, Beuerman RW, Dick T, Liu S (2016) Amphiphilic xanthones as a potent chemical entity of anti-mycobacterial agents with membrane-targeting properties. Eur J Med Chem 123: 684-703. PMI: 27517813
Hotra A, Suter M, Biukovic G, Ragunathan P, Kundu S, Dick T, Gruber G (2016) Deletion of a unique loop in the mycobacterial F-ATP synthase gamma subunit sheds light on its inhibitory role in ATP hydrolysis-driven H(+) pumping. FEBS J 283: 1947-1961. PMI: 26996828
Gopal P, Yee M, Sarathy J, Low JL, Sarathy JP, Kaya F, Dartois V, Gengenbacher M, Dick T (2016) Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis. ACS Infect Dis 2: 616-626. PMI: 27759369
New Anti-Tubercular Compounds Targeting F-ATP Synthase. G. Grueber, R.W. Bates; A. Horta; T. Dick. Singapore patent application No.: 10201701210T; February 15, 2017.
Bortezomib As An Inhibitor Of Mycobacterial Caseinolytic Protease For Treatment Of Tuberculosis. T. Dick, W. Moreira, E. Rubin, R. Raju and B. Chia. International Application No.: PCT/US20160/16658; February 4, 2016.
New Dipeptidyl Boronates As Inhibitors Of Mycobacterial Caseinolytic Protease For The Treatment Of Tuberculosis. B Dymock, A Poulsen, T Dick, W Moreira, S Santhanakrishnan. Singapore application No.: 10201609299R; November 7, 2016.
Dr Dick has 20 years of experience in mycobacteriology, antibacterial drug discovery and R and D program management. His research focuses on Non-Tuberculous Mycobacteria (NTM) infections and Tuberculosis (TB). Since March 2017 he is Director of Antimicrobial Drug Discovery and Associate Professor at the Public Health Research Institute (PHRI) and the Department of Medicine, New Jersey Medical School, Rutgers University. Dr Dick holds a Toh Chin Chye Visiting Professorship at the Department of Microbiology and Immunology, School of Medicine, National University of Singapore where he manages the TB drug discovery project portfolio of the School’s SPRINT-TB tuberculosis program which he co-founded in 2014. Prior to his current appointments he served 5 years as Director of the BSL3 Core Facility and Associate Professor at the National University of Singapore. Before he joined the National University Dr Dick worked for eight years in the pharmaceutical industry where he established and led the TB disease area at the Novartis Institute for Tropical Diseases, Singapore. He managed the discovery portfolio from target identification to preclinical development, and represented the industry partner in the Gates- and Wellcome-funded Grand Challenges in Global Health 11 consortium. To facilitate translational research he created a joint clinical research operation between Novartis, the Eijkman Institute and Hasanuddin University in Indonesia. Dr Dick completed his post-doctoral fellowship at the Institute of Molecular and Cell Biology in Singapore, where he became principal investigator heading the Mycobacterium Biology Laboratory. He studied biochemistry, genetics and microbiology at the University of Heidelberg where he obtained his PhD in molecular bacteriology.